MedTrace Logo

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

NCT00461344 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-04-03

No results posted yet for this study

Summary

Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer

Secondary:

* Clinical response rate
* To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer
* Type of surgery (radical/conservative)

Conditions

  • Ductal Carcinoma

Interventions

DRUG

Docetaxel

DRUG

Doxorubicin

Sponsors & Collaborators

Principal Investigators

  • László Erős · sanofi-aventis Hungary

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-06-30
Completion
2007-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461344 on ClinicalTrials.gov